Skip to content

    Zim Laboratories Limited

    ZIMLAB
    Healthcare·17 Nov 2025
    Management Summary

    Zim Laboratories reported a sequential improvement in Q2 FY26, with total operating income rising 23.6% to INR887 million and EBITDA margins expanding to 8.8%. The pharmaceutical segment drove this growth, increasing 30.7% QoQ. However, overall revenue growth was tempered by a decline in the nutraceutical segment due to deferred institutional orders, and the company recorded a net loss of INR4 million, albeit significantly reduced from the previous quarter. The company is actively addressing EU-GMP remediation and expects normalization in H2 FY26.

    Highlights

    5

    • Total operating income stood at INR887 million, marking a 23.6% sequential increase.

    • EBITDA improved to INR78 million, with margins rising to 8.8% from 7.9% in Q1 FY26.

    • PAT narrowed to a loss of INR4 million compared to a loss of INR19 million in the previous quarter.

    • The Pharmaceutical business grew 30.7% quarter-on-quarter, contributing 83% of total revenue at INR732 million.

    • Export revenue stood at INR728 million, reflecting 21% sequential improvement.

    Concerns

    3

    • Overall revenue growth was moderated by a decline in the nutraceutical segment, primarily due to deferred domestic institutional orders.

    • The Nutra segment accounted for 17% or INR155 million, with decline primarily due to softer domestic demand, moderating from INR50 million in Q1.

    • The company reported a net loss of INR4 million for the quarter.

    What Changed2

    vs Q3 FY26

    Guidance items6 → 8 (+2)Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    09 metrics
    1. 01Total Operating Income887 Mn+23.6%QoQ
    2. 02EBITDA78 Mn
    3. 03EBITDA Margin8.8%+0.9%QoQ
    4. 04PAT-4 Mn
    5. 05R&D Spend76 Mn

    Segment breakdown

    • Pharmaceutical732 Mn82.5%
    • Nutraceutical155 Mn17.5%
    Donut· Share of Revenue

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    tied up our borrowings

    Debt

    Gross ₹117 crores

    Guidance & targets

    8
    CategoryTargetPriority
    Revenue
    FY26 Revenue
    in the range of FY '25 revenues broadly in line with last year
    		Medium
    Profitability
    H2 FY26 EBITDA
    similar to the last year
    		Medium
    Product Launch
    NIP product sales for EU market
    start from Q1 or Q2
    		High
    Product Launch
    Tamsulosin + Dutasteride commercial supplies
    start within the next 6 months
    		High
    Regulatory
    EU-GMP audit completion
    complete by March '26
    		High
    Regulatory
    Supplies resumption post EU-GMP
    resume by Q1 or Q2
    		High
    Segment Performance
    Nutra segment normalization
    normalization
    		High
    Segment Performance
    NIP and OTF sales run rate
    INR15 crores, INR16 crores
    		High

    EU-GMP audit completion

    March '26
    CurrentOngoing remediation
    TargetAudit completed

    Why it matters

    Reinstatement of EU-GMP accreditation is crucial for unlocking value in regulated markets and resuming supplies.

    working on an aggressive target time line to complete the EU-GMP audit by March '26

    How to verify

    guidance_and_targets[metric='EU-GMP audit completion']

    Risks & concerns

    4
    RiskSeverity

    EU-GMP non-compliance and its impact on regulated markets

    The EU-GMP suspension is a critical issue impacting sales in regulated markets, but the company has an accepted CAPA plan and is working towards re-accreditation by March '26. — Management acknowledged

    high

    Decline in nutraceutical segment due to deferred institutional orders

    The Nutra segment saw a decline due to delays in domestic institutional orders, which are expected to materialize in H2 FY26. — Management acknowledged

    medium

    Potential margin impact from site transfers and contract manufacturing

    While site transfers to third-party CMOs will have some cost implications, the company expects the impact on overall margins to be marginal due to product pricing and agreements. — Management downplayed

    low

    Over-reliance on manual documentation leading to compliance issues

    The 'fraud' observation was linked to incomplete manual logbooks, prompting a shift to electronic documentation and improved quality culture to prevent future issues. — Management acknowledged

    medium

    Q&A highlights

    8

    “The report that we received initially was about the possibility to commit fraud. There was a manual book which daily -- actually where the engineers are supposed to give a daily record of the upstream and downstream pressure in the air handling unit, which applies to a core area, which is supposed to be written there. So that was incomplete and there was a pen inside left behind by the technician.”

    Management clarified the nature of the critical observation, attributing it to incomplete manual documentation rather than intentional fraud, and detailed remediation steps.

    asked by Shreya Chatterjee

    2 min read7 chapters

    Detailed Narrative

    01

    Q2 FY26 Performance Overview

    Zim Laboratories reported a sequential improvement in Q2 FY26, with total operating income reaching INR887 million, a 23.6% increase from the previous quarter. EBITDA improved to INR78 million, with margins rising to 8.8% from 7.9% in Q1 FY26. The company narrowed its net loss to INR4 million, significantly better than the INR19 million loss in Q1 FY26, reflecting improved operating efficiency.

    02

    Pharmaceutical Segment Drives Growth

    The pharmaceutical business was the primary growth driver, contributing 83% of total revenue at INR732 million, and growing 30.7% quarter-on-quarter. Export revenue also saw a 21% sequential improvement, reaching INR728 million, supported by better traction in core business and steady execution across key markets. The NIP and OTF portfolio contributed INR81 million to this performance.

    03

    Nutraceutical Segment Decline and Expected Recovery

    Overall revenue growth was moderated by a decline in the nutraceutical segment, which accounted for 17% or INR155 million of total revenue. This decline was primarily attributed to the deferment of some domestic institutional orders, with revenues moderating to INR38 million from INR50 million in Q1. Management expects normalization in the Nutra business during H2 FY26 as these orders materialize.

    04

    EU-GMP Remediation and Strategic Priorities

    The company's highest strategic priority remains EU-GMP remediation and CAPA implementation. Management is working towards an aggressive target timeline to complete the EU-GMP audit by March '26, with supplies expected to resume by Q1 or Q2 FY27. They have instituted a switch to electronic documentation to address observations related to manual record-keeping and hired both Indian and European consultants to aid in the process.

    05

    Business Continuity through Site Transfers

    To maintain business continuity amidst regulatory challenges🌐, Zim Laboratories has initiated site transfer projects for select key products. For instance, the transfer of Tamsulosin + Dutasteride to a PGA approved site has commenced, with commercial supplies expected within the next 6 months. Similar strategies are being executed for Dimethyl Fumarate and azithromycin suspension to ensure uninterrupted supply from EU and MHRA-approved facilities.

    06

    R&D Investment and Pipeline Development

    The company invested INR76 million in R&D during the quarter, focusing on new product development, bioequivalence studies, and regulatory filings. This investment aims to strengthen the innovative product pipeline and accelerate filing activity across emerging and regulatory markets. The company continues to file MAs for off-patent products and expects some products to go off-patent in 2027 and 2028.

    07

    Working Capital and Debt Management

    Inventory days increased from 83 to 109 days, primarily due to building up stock for a robust order book and anticipated sales in H2 FY26 to compensate for a shortfall in H1. The company's total debt stands at approximately INR117 crores, comprising INR66 crores in term loans and INR51 crores in cash credit. Management stated there would be no further debt increase, and term loan repayments have already commenced.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.